Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score
AbstractWe examined the predictive ability of the new thrombophilia-based genetic risk score that has been developed (TiC-RPL) to acutely determine the risk of recurrent pregnancy loss (RPL) closely related to thrombophilia and to compare it with the ability of the classical genetic thrombophilia variants F5 rs6025 and F2 rs1799963. This is a case-control observational study, with retrospective data analysis. We included 180 healthy women with at least one uncomplicated pregnancy to term and no previous miscarriage and 184 cases of idiopathic recurrent pregnancy loss (RPL). The predictive ability was assessed in terms of discrimination (AUC), sensitivity, specificity, positive and negative predictive values (PPV, NPV), and positive and negative likelihood ratios (PLR and NLR). TiC-RPL has a better AUC (95 CI) than F5 rs6025+F2 rs1799963 [0.763 (0.715-0.811) vs 0.540 (0.514-0.567); p<0.0001], with a sensitivity of 70.65%, a specificity of 67.78%, a PPV of 69.15%, an NPV of 69.32%, a PLR of 2.19, and an NLR of 0.43. Our results show that the new score TiC-RPL is significantly better than F5 rs6025+F2 rs1799963 in identifying RPL women in whom RPL appears to be associated with thrombophilia. This identification can guide a personalized approach in the prevention of RPL.
. Martinelli I, Bucciarelli P, Mannucci PM. (2010) Thrombotic risk factors: basic pathophysiology. Crit Care Med 38(2 Suppl):S3-9.
. Mannucci PM, Franchini M. (2014) The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism. Expert Rev Hematol 7(6):757-765.
. Cao Y, Zhang Z, Xu J, et al. (2013) The association of idiopathic recurrent pregnancy loss with polymorphisms in hemostasis- related genes. Gene 530(2):248-252.
. Ziakas PD, Poulou LS, Pavlou M, Zintzaras E. (2015) Thrombophilia and venous thromboembolism in pregnancy: A meta- analysis of genetic risk. Eur J Obstet Gynecol Reprod Biol 191:106-111.
. Rai R, Regan L. (2006) Recurrent miscarriage. Lancet 368:601-611.
. Cohn DM, Goddijn M, Middeldorp S, Korevaar JC, Dawood F, Farquharson RG. (2010) Recurrent miscarriage and antiphospho- lipid antibodies: Prognosis of subsequent pregnancy. J Thromb Haemost 8(10):2208-2213.
. Middeldorp S. (2014) Anticoagulation in pregnancy complications. Hematology (1):393-399.
. Simcox LE, Ormesher L, Tower C, Greer IA. (2015) Thrombophilia and Pregnancy Complications. Int J Mol Sci 16(12):28418-28
. Soria JM, Morange P-E, Vila J, et al. (2014) Multilocus genetic risk scores for venous thromboembolism risk assessment. J Am Heart Assoc 3(5):e001060.doi:10.1161/JAHA.114.001060.
. Gu W, Pepe MS. (2009) Estimating the capacity for improvement in risk prediction with a marker. Biostatistics. 10(1):172- 186.
. Skeith L, Carrier M, Kaaja R, et al. (2016) A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. Blood 127(13):1650-1655.
. Sergi C, Al Jishi T, Walker M. (2014) Factor V Leiden mutation in women with early recurrent pregnancy loss: a meta-analysis and systematic review of the causal association. Arch Gynecol Obstet 291(3):671-679.
. Rey E, Kahn SR, David M, Shrier I. (2003) Thrombophilic disorders and fetal loss: a meta-analysis. Lancet (London, England) 361(9361):901-908.
. Battinelli EM, Marshall A, Connors JM. (2013) The Role of Thrombophilia in Pregnancy.Thrombosis 516420. doi:10.1155/2013/516420.
. Bates SM, Greer I a, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO. (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S-736S.
. George L, Granath F, Johansson ALV, Olander B, Cnattingius S. (2006) Risks of repeated miscarriage. Paediatr Perinat Epidemiol 20(2):119-126.
. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. (2000) Maternal age and fetal loss: population based register linkage study. BMJ 320(7251):1708-1712.
. Smith ML, Schust D. (2011) Endocrinology and Recurrent Early Pregnancy Loss. Semin Reprod Med 29(6):482-490.
. Bradley LA, Palomaki GE, Bienstock J, Varga E, Scott JA. (2012) Can Factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes?: Results from a targeted evidence-based review. Genet Med Genet Med 1414(11):39-50.
. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. (2003) Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 361(9367):1424-1431.
. Dossenbach-Glaninger A, van Trotsenburg M, Oberkanins C, Atamaniuk J. (2013) Risk for Early Pregnancy Loss by Factor XIII Val34Leu: The Impact of Fibrinogen Concentration. J Clin Lab Anal 27(6):444-449.
. Ogasawara MS, Aoki K, Katano K, Ozaki Y, Suzumori K. (2001) Factor XII but not protein C, protein S, antithrombin III, or factor XIII is a predictor of recurrent miscarriage. Fertil Steril 75(5):916-919.
. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. (2006) Factor XIII Val34Leu variant is protective against venous thromboembolism: A HuGE review and meta-analysis. Am J Epidemiol 164(2):101-109.
. Song J, Chen F, Campos M, et al. (2015) Quantitative Influence of ABO Blood Groups on Factor VIII and Its Ratio to von Willebrand Factor, Novel Observations from an ARIC Study of 11,673 Subjects. Miyata T, ed. PLoS One 10(8):e0132626. doi:10.1371/journal.pone.0132626.
. Dossenbach-Glaninger A, van Trotsenburg M, Krugluger W, et al. (2004) Elevated coagulation factor VIII and the risk for recurrent early pregnancy loss. Thromb Haemost 91(4):694-699.
. Marietta M, Facchinetti F, Sgarbi L, et al. (2003) Elevated plasma levels of factor VIII in women with early recurrent miscarriage. J Thromb Haemost 1(12):2536-2539.
. Abu-Heija A. (2014) Thrombophilia and Recurrent Pregnancy Loss: Is heparin still the drug of choice? Sultan Qaboos Univ Med J 14(1):e26-36.
. Gallagher EJ. (1998) Clinical Utility of Likelihood Ratios. Ann Emerg Med March 31:391-397
. Greenland P. (2008) Comments on “Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond” by M.J. Pencina, R.B.D’ Agostino Sr, R.B. D’ Agostino Jr, R.S. Vasan, Statistics in Medicine (DOI:10.1002/sim.2929). Stat Med 27(2):188-190. doi:10.1002/sim.2976.
. Attia J. (2003) Moving beyond sensitivity and specificity: using likelihood ratios. Aust Prescr 26:111-113.
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.